[go: up one dir, main page]

WO2004005882A3 - Multi-parameter high throughput screening assays (mphts) - Google Patents

Multi-parameter high throughput screening assays (mphts) Download PDF

Info

Publication number
WO2004005882A3
WO2004005882A3 PCT/US2002/019457 US0219457W WO2004005882A3 WO 2004005882 A3 WO2004005882 A3 WO 2004005882A3 US 0219457 W US0219457 W US 0219457W WO 2004005882 A3 WO2004005882 A3 WO 2004005882A3
Authority
WO
WIPO (PCT)
Prior art keywords
mphts
assays
throughput screening
high throughput
screening assays
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/019457
Other languages
French (fr)
Other versions
WO2004005882A2 (en
Inventor
C Anthony Altar
Jeffrey A Brockman
David Evans
Derek Hook
Leszek Klimczak
Pascal Laeng
Michael Palfreyman
Prithi Rajan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Psychiatric Genomics Inc
Original Assignee
Psychiatric Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psychiatric Genomics Inc filed Critical Psychiatric Genomics Inc
Priority to AU2002368043A priority Critical patent/AU2002368043A1/en
Anticipated expiration legal-status Critical
Publication of WO2004005882A2 publication Critical patent/WO2004005882A2/en
Publication of WO2004005882A3 publication Critical patent/WO2004005882A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to screening methods and assays that are referred to herein as multi-parameter hight throughput screening (MPHTS) assays. These MPHTS assays are useful for identifying candidate pharmaceutical compounds. In particular, the screening methods of this invention may be used to identify compounds that have potential therapeutic benefits for the treatment of neuropsychiatric and neurodegenerative disorders, including schizophrenia, bipolar affective disorder (BAD), autism and Alzheimer's disease to name a few.
PCT/US2002/019457 2001-06-18 2002-06-18 Multi-parameter high throughput screening assays (mphts) Ceased WO2004005882A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002368043A AU2002368043A1 (en) 2001-06-18 2002-06-18 Multi-parameter high throughput screening assays (mphts)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US29915101P 2001-06-18 2001-06-18
US60/299,151 2001-06-18
US31782801P 2001-09-07 2001-09-07
US60/317,828 2001-09-07
US32515001P 2001-09-25 2001-09-25
US60/325,150 2001-09-25
US33304701P 2001-11-14 2001-11-14
US60/333,047 2001-11-14
US34993602P 2002-01-18 2002-01-18
US60/349,936 2002-01-18
US36183402P 2002-03-04 2002-03-04
US60/361,834 2002-03-04

Publications (2)

Publication Number Publication Date
WO2004005882A2 WO2004005882A2 (en) 2004-01-15
WO2004005882A3 true WO2004005882A3 (en) 2005-01-27

Family

ID=30119502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019457 Ceased WO2004005882A2 (en) 2001-06-18 2002-06-18 Multi-parameter high throughput screening assays (mphts)

Country Status (2)

Country Link
AU (1) AU2002368043A1 (en)
WO (1) WO2004005882A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE102004016437A1 (en) * 2004-04-04 2005-10-20 Oligene Gmbh Method for detecting signatures in complex gene expression profiles
WO2005108598A1 (en) 2004-05-11 2005-11-17 Axiogenesis Ag Assay for drug discovery based on in vitro differentiated cells
US7972793B2 (en) 2009-11-04 2011-07-05 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US7951542B2 (en) 2009-11-04 2011-05-31 Surgene, LLC Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US7985551B2 (en) 2009-11-04 2011-07-26 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US7951543B2 (en) 2009-11-04 2011-05-31 Suregene, Llc Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
CN111826436B (en) * 2020-07-21 2022-10-04 国家烟草质量监督检验中心 Group high-throughput determination method for gene and corresponding protein expression change in hippocampal tissues in nicotine addiction, withdrawal and addiction reconstruction stages

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] XP002903971, accession no. NCBI Database accession no. M22357 *
HAKAK ET AL.: "Genome-Wide Expression Analysis Reveals Dysregulation of Myelination-Related Genes in Chronic Schizophrenia", PNAS, vol. 98, no. 8, 2001, pages 4746 - 4751, XP002957625 *
HAUGABOOK ET AL: "High Throughput Screens for the Identification of Compounds that Alter the Accumulation of the Alzheimer's Amyloid B Peptide (AB).", JOURNAL OF NEUROSCIENCE METHODS, vol. 108, 2001, pages 171 - 179, XP002958534 *
SAUNDERS: "Gene Identification in Alzheimer's Disease.", PHARMACOGENOMICS, vol. 2, no. 3, 2001, pages 239 - 249, XP008040120 *
SHOEMAKER ET AL: "Application of High Throughput, Molecular-Targeted Screening to Anticancer Drug Discovery", CURRENT TROPICS IN MED. CHEM., vol. 2, no. 3, 2002, pages 229 - 246, XP002903970 *
US NATIONAL OF MEDICINE: "Two Forms of 1B236/Myelin-Associated Glycoprotein, a Cell Adhesion Molecule for Postnatal Neural Development, are Produced by Alternative Splicing", PNAS, vol. 84, no. 12, 1987, BETHESDA, MARYLAND, USA, pages 4337 - 4341 *

Also Published As

Publication number Publication date
WO2004005882A2 (en) 2004-01-15
AU2002368043A8 (en) 2004-01-23
AU2002368043A1 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
WO2003042654A3 (en) Multi-parameter high throughput screening assays (mphts)
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
NO20011891L (en) Use of radioligands for screening of inhibitors of amyloid <beta> peptide production
DE60336848D1 (en) IMMUNOGENOUS AND CORRESPONDING ANTIBODIES SPECIFIC FOR COMMON HIGH-MOLECULAR AGGREGATION INTERMEDIATE PRODUCTS OF AMYLOIDS FROM PROTEINS OF DIFFERENT SEQUENCE
DE69429527D1 (en) INHIBITORS OF BETA AMYLOID PROTEIN PRODUCTION
WO2002085285A3 (en) Methods and reagents for regulating bone and cartilage formation
EA200200293A1 (en) BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS
DE60224383D1 (en) PROCEDURE FOR DETECTION IN YEAST TO INFLUENCE PROTEIN FOLDING
BR0314721A (en) Tricyclic compounds useful for treating inflammatory and allergic disorders, processes for their preparation and pharmaceutical compositions containing them
WO2001087354A3 (en) Use of small molecule radioligands for diagnostic imaging
AR045004A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE 11-PIPERAZIN-1-ILDIBENZO [B, F] [1,4] TIAZEPINA
WO2002064618A3 (en) Methods of identifying agents that mediate polypeptide aggregation
WO2004005882A3 (en) Multi-parameter high throughput screening assays (mphts)
WO2004032975A3 (en) Biphenyls and fluorenes as imaging agents in alzheimer's disease
DE60034117D1 (en) METHOD FOR PRODUCING GONADOTROPINE COMPOSITIONS
DE602004026683D1 (en) METHOD FOR DIAGNOSIS AND MONITORING OF NEUROLOGICAL ILLNESSES BY DETECTION OF ENCEPHALOTOXIN
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
EP1724588A3 (en) Diagnostic screens for Alzheimer's disease
WO2006042137A3 (en) Methods for identifying parkinson's disease therapeutics
CA2359357A1 (en) Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances
EP1233075A3 (en) BDNF polymorphism and association with bipolar disorder
DE602004024992D1 (en) USE OF PYRAZOLOPYRIDINES FOR THE TREATMENT OF COGNITIVE DEFICITES
WO2001049871A3 (en) Process for finding a protease inhibitor
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
WO2003087408A3 (en) Schizophrenia associated genes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM EC EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP